OncoMatch/Clinical Trials/NCT06435351
Personalized Dendritic Cell Vaccine Pilot for High Risk TNBC After Neoadjuvant Therapy
Is NCT06435351 recruiting? Yes, currently enrolling (May 2026). This Early Phase 1 trial studies Dendritic Cell (DC) Vaccine for breast cancer.
Treatment: Dendritic Cell (DC) Vaccine — This is a pilot protocol to evaluate the safety, feasibility, and immunogenicity of a personalized breast cancer vaccine based utilizing whole exome sequencing data of a patient's residual breast tumor following neoadjuvant chemotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Breast Carcinoma
Triple-Negative Breast Cancer
Biomarker criteria
Required: ESR1 expression ≤ 10% (≤ 10%)
ER/PR less than or equal to 10%
Required: PR (PGR) expression ≤ 10% (≤ 10%)
ER/PR less than or equal to 10%
Required: HER2 (ERBB2) negative by FISH and/or IHC (negative)
HER2 negative by FISH and/or IHC
Disease stage
Required: Stage II, III
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: neoadjuvant systemic chemotherapy — neoadjuvant
treated with standard of care neoadjuvant systemic chemotherapy
Must have received: surgical resection — post-neoadjuvant
surgical resection with significant residual breast tumor (equivalent to RCB II or III) disease
Lab requirements
Blood counts
adequate organ and marrow function
Kidney function
adequate organ and marrow function
Liver function
adequate organ and marrow function
Patients must have adequate organ and marrow function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Moffitt Cancer Center · Tampa, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify